Outcome of Board Meeting

November 04, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, P. J. Towers, Dalal Street, Bandra Kurla Complex, Mumbai Samachar Marg, Bandra (East), Mumbai - 400 001 Mumbai - 400 051 Symbol: LUPIN Scrip Code: Equity -500257 Subject: Outcome of the Board Meeting - Unaudited Financial Results for the quarter and half year ended September 30, 2026 Dear Sir/Madam, Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company, at its meeting held on Tuesday, November 03, 2026, inter alia, unanimously approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026. The said Unaudited Financial Results along with the Limited Review Reports of the Statutory Auditors thereon are enclosed herewith. The Board meeting commenced on November 03, 2026, at 07:30 p.m. (IST) and concluded on November 04, 2026, at 12:25 a.m. (IST). The above is for your information and dissemination. Thanking you, For LUPIN LIMITED AMIT KUMAR GUPTA COMPANY SECRETARY & COMPLIANCE OFFICER (ACS -15754) Encl.: a/a LUPIN LIMITED Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 info@lupin.com | www.lupin.com LUPIN LIMITED Registered Office: 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055. Corporate Identity Number: L24100MH1983PLC029442 Tel: (91-22) 6640 2323 E-mail: info@lupin.com Website: www.lupin.com L U P I N STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2026 (₹ in million) Particulars Quarter Quarter Quarter Six months Six months Year Ended Ended Ended Ended Ended Ended 30/09/2026 30/06/2026 30/09/2025 30/09/2026 30/09/2025 31/03/2026 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) 1) Revenue from operations a) Sales / income from operations 35,282.9 71,124.6 38,527.9 106,407.5 94,582.0 190,444.2 b) Other operating income 390.5 594.4 2,154.9 984.9 3,186.7 4,682.4 Total Revenue from operations 35,673.4 71,719.0 40,682.8 107,392.4 97,768.7 195,126.6 2) Other income 955.2 1,024.8 700.0 1,980.0 1,241.4 3,127.7 3) Total income (1+2) 36,628.6 72,743.8 41,382.8 109,372.4 99,010.1 198,254.3 4) Expenses a) Cost of materials consumed 10,142.7 10,505.5 8,641.4 20,648.2 17,732.8 36,783.6 b) Purchases of stock-in-trade 3,388.6 3,089.0 3,096.8 6,477.6 6,216.1 11,923.2 c) Changes in inventories of finished goods, (810.8) (99.6) 954.4 (910.4) 556.9 46.6 work-in-progress and stock-in-trade [(increase)/decrease] d) Employee benefits expense 7,469.8 7,196.9 6,088.3 14,666.7 12,527.2 25,448.8 e) Finance cost 325.5 355.6 277.8 681.1 466.8 1,214.7 f) Depreciation, amortisation and impairment expense 1,931.2 1,900.1 1,747.2 3,831.3 3,514.5 7,071.8 g) Other expenses 14,230.8 13,619.9 12,148.6 27,850.7 24,170.5 49,159.8 h) Net (gain) / loss on foreign currency transactions (860.4) 75.8 (2,003.0) (784.6) (2,487.5) (6,271.0) Total expenses 35,817.4 36,643.2 30,951.5 72,460.6 62,697.3 125,377.5 5) Profit / (Loss) before exceptional item and tax (3-4) 811.2 36,100.6 10,431.3 36,911.8 36,312.8 72,876.8 6) Exceptional items [income/(expense)] (Refer note 5) (769.3) - 5,926.8 (769.3) 5,926.8 4,065.7 7) Profit / (Loss) before tax (5+6) 41.9 36,100.6 16,358.1 36,142.5 42,239.6 76,942.5 8) Tax expense (net) Current tax 32.3 8,925.7 2,872.3 8,958.0 7,387.7 13,512.9 Deferred tax 68.7 28.9 (87.7) 97.6 (2.3) (236.0) Total tax expense 101.0 8,954.6 2,784.6 9,055.6 7,385.4 13,276.9 9) Net Profit / (Loss) after tax (7-8) (59.1) 27,146.0 13,573.5 27,086.9 34,854.2 63,665.6 10)Other Comprehensive Income / (Loss) (a) (i) Items that will not be reclassified subsequently to (43.4) (0.8) 196.3 (44.2) 92.8 61.8 profit or loss (ii) Income tax relating to items that will not be reclassified 15.1 0.3 (68.6) 15.4 (32.4) (21.6) subsequently to profit or loss (b) (i) Items that will be reclassified subsequently to profit or 51.8 109.2 (437.9) 161.0 (365.1) (324.3) loss (ii) Income tax relating to items that will be reclassified (18.2) (38.1) 153.0 (56.3) 127.6 113.3 subsequently to profit or loss Other Comprehensive Income / (Loss), net of tax 5.3 70.6 (157.2) 75.9 (177.1) (170.8) 11)Total Comprehensive Income / (Loss), net of tax (9+10) (53.8) 27,216.6 13,416.3 27,162.8 34,677.1 63,494.8 12)Paid up equity share capital (Face value ₹ 2/- each) 914.6 914.5 913.6 914.6 913.6 914.4 13)Other equity 300,423.3 14)Earnings per share (of ₹ 2/- each) (Not annualised for the quarters and six months ended) (A) Before exceptional items 'a) Basic (in ₹) 1.55 59.37 18.42 60.92 65.01 129.18 'b) Diluted (in ₹) 1.55 59.27 18.37 60.61 64.84 128.84 (B) After exceptional items 'a) Basic (in ₹) (0.13) 59.37 29.72 59.24 76.32 139.38 'b) Diluted (in ₹) (0.13) 59.27 29.65 58.94 76.12 139.01 See accompanying notes to the standalone financial results. continued on Page 2.. ….. Page 2 ….. NOTES: 1. TheaboveStandaloneFinancialResultswerereviewedbytheAuditCommitteeonNovember02,2026andthereafterapprovedandtaken onrecordbytheBoardofDirectorsattheirmeetingheldonNovember03,2026.TheStatutoryAuditorsoftheCompanyhavecarriedout limited review of the above Standalone Financial Results pursuant to Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. 2. The Standalone Financial Results are prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended. 3. DuringthequarterendedSeptember30,2026,57,436(yeartodate110,861)equitysharesof₹2/-each,fullypaid-up,wereallottedupon exerciseofthevestedstockoptionspursuanttotheLupinEmployeesStockOptionPlans(ESOPs),resultinginanincreaseinthepaid-up equityshare capital by₹0.1 million(year todate ₹0.2 million)and securitiespremium accountby₹87.1 million(year todate ₹164.0 million). 4. AsapprovedbytheMembersoftheCompanyatthe44thAnnualGeneralMeetingheldonAugust04,2026,theCompanyhasdisbursedon August 06, 2026 a final dividend of ₹ 18/- per equity share of the face value of ₹ 2/- each aggregating ₹ 8,230.2 million. 5. Exceptional items a. During the quarter ended and six months ended September 30, 2026, the Company has determined that the carrying value of investment in a subsidiary is higher than the recoverable amount and has provided for diminution in the value of investment of ₹ 769.3 million. b. TheCompanyanditssubsidiaryareexposedtomultiplecivillawsuitsalleginganticompetitivebehaviorrelatedtocertainproductsanda possibleviolationoffederalandstateantitrustlaws.TheselawsuitswerecombinedintothecollectionofsimilarcasesreferredtoasIn Re Generic Pharmaceuticals Antitrust Litigation. Such litigation are often resolved through settlement agreements. During the year endedMarch312026,theCompanyonbestestimaterecordedaprovisionof₹4,493.9million(USD50.0million)towardsthislitigation without admission of liability or wrongdoing. During the quarter ended March 31, 2026, this provision has been recorded by the subsidiary and consequently reversed in the standalone results. During the period ended September 30, 2026, the wholly owned subsidiarysettledoneoftheongoingantitrustmattersforanamountof₹3,162.8million(USD35.8million)withoutadmissionofliability or wrongdoing. c. On February09, 2026, Lupin Limited and its subsidiary entered into a settlement agreement with Astellas towards ongoing dispute relatedtoMirabegronERTabletsagenericversionofMyrbetriqERTabletsinUSmarketsandagreedtopayUSD90.0million.During theyearendedMarch31,2026,theCompanyhascompensatedLupinPharmaceuticals,Inc.,U.S.A.,forthesettlementpaymentof₹ 1,364.7 million (USD15.0 million) made byit and accordinglyexpensed. The bal [Showing first 8,000 characters — download PDF for full document]